
30 institutions participating in this Trial Grateful to this amazing network !!!

👨⚕️#Nephrologist M.D. Head of @parisTxgroup. PhD #1 in Cell Biology 🧫 PhD #2 in Biostatistics 📊. Passionate about improving #Patient Care by #innovation

30 institutions participating in this Trial Grateful to this amazing network !!!

A new study identifies 7 distinct FEV1 trajectories post #LungTransplantation, each telling a different story of survival- should we consider personalized, trajectory-based monitoring of lung recipients? 🫁 @Raynaud_Maths, @drAntoineRoux, @AlexandreLoupy 🔗: jhltonline.org/article/S1053…

CONFIDENCE trial: In persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results and Research Summary: nej.md/4jEVbbk

📢 Just out in @NatureComms & presented @ESOTtransplant ! Our study "Impact of HLA evolutionary divergence and molecular mismatches on AMR of kidney allografts" is now published. 🔗nature.com/articles/s41467-0… 🙌to @zpdemir2 Carmen Lefaucheur @AlexandreLoupy

🔬 A look at the top-tier journals in medicine and biomedical science interesting! congratulation on these top tier journals🚀🦾🚀🤩 •The Lancet IF: 98.4 •NEJM IF: 96.2 •The BMJ IF: 93.6 •Nature Medicine IF: 50.0 •JAMA IF: 50.0 •Nature IF: 48.5

From @ESOTtransplant #esotcongress 2025 2 amazing days working with colleagues on the @TheLancet commission. Paving the future of organ transplantation in the next 15 years !!!

Great thing about having the Lancet commission meeting ahead of #ESOT2025 is that you can see an empty congress space quiet before the storm ! looking forward to meeting with colleagues and friends and share science !! @gabriel_oniscu

📢 New publication in Xenotransplantation Journal by our group @ParisTxGroup @AlexandreLoupy ! Among the 2,900+ Xeno papers we assessed, 706 focused on solid organ & islet transplants from animals to humans 🐷➡️🧍 lnkd.in/eVKHzNVn Here’s a summary of what we found 👇

Beyond standard of care monitoring for patients who are post-transplant, urinary chemokine CXCL9 demonstrated limited clinical utility, while CXCL10 provided no additional value. kidney.pub/JASN0742 #ASNJASN


Direct from Choose Europe 🇪🇺for Science: A Bold Step from Paris 🇫🇷 ! Transplant researchers: if you’re ready to innovate, 🇫🇷 might be your next destination🛬. @ParisTxGroup is ready 🚀🤖🦾#PITOR #FranceForScience DM me if interested


Thank you 🙏 for an amazing event and so many bright people ! go Mayo !
@MayoClinicNeph , Hypertension and Kidney Transplantation Update for the Clinician 2025 from Kidney stones to AI in Tx fantastic presentations @AlexandreLoupy @keddis_mira @lieske_john


Proud of my team @ParisTxGroup and the amazing work done for @ESOTtransplant abstract submission! We are proud of the research submitted in kidney - Heart - Lung - Liver and Xeno ! addressing key challenges and encompassing large trials and cutting edge technologies. @gabriel_oniscu @Olivier_Thaunat

Interested in our team’s @NEJM publication on microvascular inflammation in kidney allografts and its clinical outcomes? Check out the coverage in @pathologistmag, highlighting the key findings and the study’s impact. thepathologist.com/subspecia…